India's Potential Foreign Investors Face Hurdle In High Court Setting Prices
This article was originally published in PharmAsia News
Executive Summary
Potential foreign investors in India's pharmaceutical industry are finding a recent announcement easing restrictions on some investments had little effect as the regulatory system and now the Supreme Court is about to become the price-control policymaker.
Potential foreign investors in India's pharmaceutical industry are finding a recent announcement easing restrictions on some investments had little effect as the regulatory system and now the Supreme Court is about to become the price-control policymaker. The court said it would act now on setting a new pricing policy if the Department of Pharmaceuticals failed to cap prices on 348 domestically produced generics. The government apparently failed to meet the deadline, adding another factor for foreign firms to consider before investing in India pharma. (Click here for more)
"India Courts Drug Disaster" - Wall Street Journal (9/26/2012)